Two new investigational antimalarial drugs developed by the U.S. Army Malaria Research Program were tested in patients with multi-drug-resistant falciparum malaria from Vietnam. WR 33063, a phenanthrene methanol, cured 13 patients treated in the United States. All of these patients had suffered multiple recrudescences after treatment with standard antimalarial drugs. In addition, 23 of 25 patients with acute attacks of falciparum malaria treated in Vietnam were cured. The rate of clinical response was prompt. WR 30090, a quinoline methanol, similarly cured eight patients with multiple recrudescences in the United States and 23 of 26 patients in Vietnam. Adverse effects associated with the drugs were not seen. These drugs signify a major advance in the chemotherapy of drug-resistant falciparum malaria.
Chloroquine treatment of patients from Vietnam with acute malaria infections due to Plasnodium falciparurn during 1964-1966 was associated with cure rates of only 11 to 20% (7) . Quinine treatment was only slightly more effective: cure rates, when this drug was used alone, were 26 to 50%. Treatment with combinations of drugs (quinine, pyrimethamine, and dapsone or chloroquine, pyrimethamine, and sulfadiazine) was much more effective: cure rates with these combinations were about 98%. However, some patients had repeated recrudescences. In addition, there were multiple side effects associated with these drug combinations. Most recently, the cure rates with quinine, pyrimethamine, and dapsone have shown an apparent decrease to 90% (A. P. Hall, Amer. J. Trop. Med. Hyg., in press). During 1967 During -1969 , some of these patients with recrudescent infections were treated in the United States with a combination of trimethoprim and sulfalene (2) . Although this combination terminated most recrudescent attacks, it produced a radical cure in only about 72% of the cases. In 1969, the results with WR 33063, an investigational phenanthrene methanol developed by the U.S. Army Malaria Research Program, were sufficiently encouraging in the U.S. Army contract clinical test centers (1) to warrant treatment of a patient from Vietnam with this drug (4 All patients were carefully observed during drug ingestion. Vomiting after drug ingestion requiring the readministration of drug did not occur. Daily examinations of peripheral blood films for malaria parasites were made for all patients until plasmodia were absent for two consecutive days. Hematocrits, white blood cell counts, and differential counts were obtained five or six times during drug administration and three or four times during the follow-up observation periods. Serum and urine were examined for evidence of hepatic or renal dysfunction five times during the study period. A single plasma specimen for measurement of drug concentration in most patients was obtained 3.5 to 4 hr after drug administration during the first 2 days of therapy, and a second specimen was obtained at the same interval after drug administration on the final day of therapy (R. T. Lofberg, in preparation).
After completion of treatment, the patients were sent to the 6th Convalescent Center at Cam Rahn Bay, Vietnam (an area non-endemic for malaria) and observed for possible recrudescence. During the observation periods, the patients received no antimalarial chemosuppressive drugs. They remained at the Convalescent Center for at least 30 days after completion of initial drug therapy.
RESULTS
All 21 patients in the first group with recrudescent falciparum malaria showed a prompt response to treatment, and none had a subsequent recrudescence during the observation periods (Table 1) . While receiving WR 33063, the first patient developed tinnitus which disappeared on the last day of therapy. No other patient had this complaint though all but one (patient 2) received twice the total amount of drug. There who had been treated with the usual combination course of oral quinine, pyrimethamine, and dapsone. The interval was 70 hr (range, 11 to 146 hr) in these patients. The rate of disappearance of detectable parasites in peripheral blood films for both drugs is illustrated in Fig. 1 . WR 30090 appeared to eliminate parasitemia more rapidly.
Some patients in group 2 had elevated serum total bilirubin or serum glutamic oxalacetic transaminase (37 of 51), abnormal urinalysis (15 of 51), or mild azotemia (5 of 51) during the initial few days of hospitalization. In all cases, these abnormalities decreased in severity during drug therapy and were attributed to the disease itself.
The mean WR 33063 concentrations in serum during the first 2 days of therapy in 21 patients and 6n the last day of therapy in 17 of the patients were 1.8 and 6.0 pg/ml, respectively. In addition, WR 33063 concentrations were determined three times during therapy in the serum of the one patient who did not have a favorable clinical response. They were 0.2, 0.4, and 0.2 #g/ml, the persistently lowest concentrations obtained. Serum (8) . No such relationship between concentrations in the blood and clinical results was seen with WR 30090.
The occurrence of many cases of vivax malaria after treatment with WR 33063 and WR 30090 during the observation period when suppressive chloroquine was withheld is consistent with the data from volunteer studies (3). However, both drugs are suppressive for P. vivwa and may be used for clinical cures of mixed infections (1, 6) . Primaquine remains the drug of choice for radical cure of P. vivax infections.
